Primary Plasma Cell Leukemia 

Authored by Samer Al Hadidi, published on 2026-07-25 21:41:52.0

  1. Primary PCL
    Confirm diagnosis and assess for presence of t(11;14)
    • Fit patients
      • VD-PACE (in most patients)
        Consider one cycle of VD-PACE at time of diagnosis (if possible) for cyto-reduction and immediate disease control. given for 2 cycles prior to tandem ASCT or as 1 cycle followed by 4-6 cycles of 4-drugs prior to tandem ASCT
        • Induction
          Preferred: 4-drugs +/-Cy (4-6 cycles) Dara-CVRd , DKRd or IsaKRD , VD/VD-PACE +/-Dara +/-IMiD
          • Tandem ASCT
            Within 3-6 months Preferred approach: MEL 200 conditioning If not available, single ASCT
            • Consolidation
              If MRD + ve or <CR: 4 cycles (Same as induction regimen) Omit if MRD – ve or CR Doses are usually modified by dose reduction to allow for tolerance
              • Extended therapy
                Until progression/ intolerance Preferred: At least 2 drugs (Carfilzomib + Lenalidomide) Combination of PI +IMiD preferred, alternative is anti-CD38 +IMiD
    • Non-fit patients
      Dose Modifications for Frail Patients (Consider dose modifications for individual medications according to frailty and organ function)
      • Prolonged induction
        8-12 cycles, 4-drug (DVRd or IsaVRd) Choice depends on tolerance and patient related factors • Avoid single agent extended therapy unless not able to tolerate combination-based therapy
        • Extended therapy
          Until progression Preferred: 2-drug Bortezomib + Lenalidomide or Daratumumab + Lenalidomide Alternative: Single agent Lenalidomide or Daratumumab
tosprivacy